Moreover, in a recent phase I trial of an antibody that blocks ligand binding to EGFR and HER3, the two patients who exhibited partial responses had SCCHN tumors that expressed high levels of HRG, suggesting a potential causal relationship between high HRG expression and activity of MEHD7495A [12], [15]. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.